Sales & Support: 314-485-5210



Catalogue number:
5 mg
Product is available in:
  • USA
  • Canada
$70.00 Shipping is calculated in checkout

Bromodomain (BET) inhibitor. SARS-CoV-2 transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4.

  • Datasheet:   view or download
  • Applications:In clinical trials for other indication(s)
Product Type:

Biochemicals & reagents

CAS Number:



1) Nicodeme et al. (2010), Suppression of inflammation by a synthetic histone mimic; Nature 468 1119 2) Mirguet et al. (2013), Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains; J.Med.Chem., 56 7501 3) Bandukwala et al. (2012), Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors; Proc.Natl.Acad.Sci.USA, 109 14532 4) Delmore et al. (2011), BET Bromodomain as a Therapeutic Strategy to Target c-Myc; Cell 146 904

Limit of Detection:


Storage Temperature:


Additional Information:

I-BET762 is a potent inhibitor of the BET family of bromodomains with no activity at bromodomains BAZ2B, SP140, ATAD2, CREBBO, and PCAF (1,2). The IC50’s for H4Ac peptide displacement: BRD2 = 32.5nM, BRD3 = 42.4nM, BRD4 = 36.1nM (1). This compound was able to suppress proinflammatory proteins by macrophage, block acute inflammation in mice (1) and suppressed the inflammatory function of T cells (3). The inhibition of BET bromodomains results in downregulation of Myc transcription which is an important oncogene (4).